RPS6KA6

Ribosomal protein S6 kinase alpha-6 · Q9UK32 · RPS6KA6 on Sugi Atlas →

10,000 patent compounds predicted against RPS6KA6, 7,630 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Hydrochloric Acid (SCHEMBL311235)	0.63	5/20
SCHEMBL311609	0.62	5/20
Hydrochloric Acid (SCHEMBL312002)	0.60	5/20
SCHEMBL310924	0.58	5/20
Hydrochloric Acid (SCHEMBL312213)	0.74	4/20
Hydrochloric Acid (SCHEMBL311202)	0.61	4/20
SCHEMBL311788	0.73	3/20
SCHEMBL311403	0.51	3/20
Ly-2584702 (SCHEMBL311653)	1.00	2/20
Ly-2584702 (SCHEMBL312564)	1.00	2/20
Tofacitinib (SCHEMBL322753)	1.00	2/20
Ly-2584702 (SCHEMBL311369)	0.98	2/20
SCHEMBL311654	0.67	2/20
SCHEMBL311708	0.59	2/20
SCHEMBL351447	0.56	2/20
SCHEMBL350642	0.54	2/20
SCHEMBL311046	0.49	2/20
SCHEMBL311060	0.45	2/20
Hydrochloric Acid (SCHEMBL311789)	0.43	2/20
Whi-P131 (SCHEMBL29295)	1.00	1/20

Clinical trials — most relevant to RPS6KA6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus	PHASE2/PHASE3	UNKNOWN
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate	PHASE2/PHASE3	WITHDRAWN
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma	PHASE1/PHASE2	COMPLETED
Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle	PHASE2	NOT_YET_RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma	PHASE1/PHASE2	COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery	PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis	PHASE1/PHASE2	COMPLETED
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus	PHASE2	COMPLETED
Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse	PHASE2	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment	PHASE1	COMPLETED
Therapeutic RSK1 Targeting in Myelofibrosis	PHASE1	RECRUITING
Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer	PHASE1	WITHDRAWN
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Testing of Micellar Casein, Blended Micellar Casein and Native Whey	nan	COMPLETED
NK Cell Deregulation in HBV Patients	nan	ACTIVE_NOT_RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
How Animal and Plant Protein Shakes Change the Body's Nutrient and Health Responses	nan	RECRUITING
ADAR1 Expression Level in Rectal Cancer	nan	RECRUITING
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation	nan	COMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Intermittent Fasting for Pancreatitis	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a RPS6KA6 binder may also engage these)

Protein	Name	Similarity
Q6PFQ0	—	1.000	Q6PFQ0 →
P18654	—	1.000	P18654 →
RPS6KA3	Ribosomal protein S6 kinase alpha-3	1.000	landscape →
P10665	—	1.000	P10665 →
RPS6KA1	Ribosomal protein S6 kinase alpha-1	1.000	landscape →
Q7TPS0	—	1.000	Q7TPS0 →
RPS6KA2	Ribosomal protein S6 kinase alpha-2	1.000	landscape →
P18652	—	0.999	P18652 →
Q63531	—	0.999	Q63531 →
Q9WUT3	—	0.998	Q9WUT3 →
Q21734	—	0.998	Q21734 →
Q5R4K3	—	0.997	Q5R4K3 →
P10666	—	0.996	P10666 →
RPS6KA5	Ribosomal protein S6 kinase alpha-5	0.996	landscape →
Q5F3L1	—	0.996	Q5F3L1 →
Q18846	—	0.995	Q18846 →
P18653	—	0.994	P18653 →
A8XJQ6	—	0.994	A8XJQ6 →
P09215	—	0.994	P09215 →
P11730	—	0.993	P11730 →
O08875	—	0.993	O08875 →
Q8C050	—	0.993	Q8C050 →
Q12706	—	0.993	Q12706 →
Q755C4	—	0.993	Q755C4 →
Q9NBK5	—	0.992	Q9NBK5 →
Q62074	—	0.992	Q62074 →
PRKCD	Protein kinase C delta type	0.992	landscape →
Q39030	—	0.992	Q39030 →
Q6U1I9	—	0.992	Q6U1I9 →
P13677	—	0.991	P13677 →